You are here: Industry Insights > Novartis

News List

Regeneron forced to drop Eylea combo, advantage Novartis pharmafile
November 28, 2017
Novartis released Phase 3 data on its leading candidate for wet age-related macular degeneration (AMD) drug and it caused a bit of a splash, as it compared strongly to Regeneron’s Eylea.
Lilly steps up to rival Pfizer, Novartis with Verzenio breast cancer approval fiercepharma
September 29, 2017
For the second time in just over six months, there’s a newcomer in a next-generation class of breast cancer-fighters.
Five firms named in breaches of ABPI code pharmatimes
September 18, 2017
Five pharma firms - Astellas UK, Astellas Europe, Pfizer, Novartis Pharmaceuticals and Tor Generics – have been named in advertisements following breaches of the ABPI Code.
ESC: Novartis faces an uphill battle turning niche drug Ilaris into a cardio blockbuster fiercepharma
August 29, 2017
Novartis plans to seek approval from the FDA to market canakinumab for preventing major cardiovascular events.
Can Novartis' Kisqali beat Pfizer's market-leading Ibrance to reimbursement in England? fiercepharma
August 25, 2017
The Swiss drugmaker’s breast cancer drug won a European green light for use in tandem with any aromatase inhibitor.
Chutes & Ladders—Novartis lures UCSF cardiovascular scientist Coughlin fiercebiotech
August 21, 2017
UCSF cardiovascular scientist Shaun Coughlin left for the Novartis Institutes for BioMedical Research to head up CV and metabolism R&D.